<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">NORGESTREL <img border="0" src="../images/pr.gif"/></span><br/>(nor-jess'trel)<br/><span class="topboxtradename">Ovrette<br/></span><b>Classifications:</b> <span class="classification">hormones and synthetic substitutes</span>; <span class="classification">progestin</span><br/><b>Pregnancy Category: </b>X<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>0.075 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Potent progestational hormone with androgenic, antiestrogenic, and anabolic properties.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Induces and maintains endometrium, preventing uterine bleeding; inhibits production of pituitary gonadotropin, preventing
         ovulation; and produces thick cervical mucus resistant to passage of sperm.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>A progestin-only contraceptive (minipill).</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Thromboembolic disorders; cerebral vascular or coronary vascular disease; carcinoma of breast, endometrium, or liver; abnormal
         vaginal bleeding; known or suspected pregnancy (category X), lactation.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Progestin-Only Contraception</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 0.075 mg/d starting on day 1 of menstrual flow, then continuing indefinitely<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Use a barrier method of contraception, when starting the minipill regimen, for the first cycle or for 3 wk to insure full
            protection.
         </li>
<li>The minipill can be started right after delivery in the nonlactation mother; however, she should be aware of an increased
            risk of thromboembolic disease during the postpartum period.
         </li>
<li>Take the minipill at same time each day, even if menstruating.</li>
<li>Store at 15°30° C (59°86° F) in a tightly closed container.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> <span class="speceff-life">Cerebral thrombosis or hemorrhage</span>, depression. <span class="typehead">CV:</span> Hypertension, <span class="speceff-life">pulmonary embolism</span>, edema. <span class="typehead">GI:</span> Nausea, vomiting, cholestatic jaundice, abdominal cramps. <span class="typehead">Urogenital:</span> <span class="speceff-common">Breakthrough bleeding,</span> cervical erosion, changes in menstrual flow, dysmenorrhea, vaginal candidiasis. <span class="typehead">Endocrine:</span> <span class="speceff-common">Weight changes; breast tenderness,</span> enlargement, or secretion. 
      <h1><a name="interactions">Interactions</a></h1>No clinically significant interactions established. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted in urine and feces as metabolites. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for S&amp;S of thrombophlebitis (see Appendix F).</li>
<li>Withhold drug and notify physician if any of the following occur: Sudden complete or partial loss of vision, proptosis, diplopia,
            or migraine headache.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Be aware that amount and duration of flow, cycle length, breakthrough bleeding, spotting, and amenorrhea vary greatly with
            use of the progestin-only contraceptive.
         </li>
<li>Wait at least 3 mo before becoming pregnant after stopping the minipill to prevent birth defects. Use a barrier method of
            contraception until pregnancy is desired.
         </li>
<li>If you have not taken all your pills and you miss a period, consider the possibility of pregnancy after 45 d from the last
            menstrual period; stop using progestin-only contraceptive until pregnancy is ruled out.
         </li>
<li>If you have taken all your pills and you miss 2 consecutive periods, rule out pregnancy and use a barrier or nonhormonal method
            of contraception before continuing the regimen.
         </li>
<li>Review package insert to ensure you understand how to use norgestrel.</li>
<li>Learn and do breast self-examination.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>